Detalles de la búsqueda
1.
Second Primary Malignancies After Commercial CAR T Cell Therapy: Analysis of FDA Adverse Events Reporting System (FAERS).
Blood
; 2024 Mar 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-38483155
2.
Two-year follow-up of lisocabtagene maraleucel in relapsed or refractory large B-cell lymphoma in TRANSCEND NHL 001.
Blood
; 143(5): 404-416, 2024 Feb 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37890149
3.
Consensus recommendations on the management of toxicity associated with CD3×CD20 bispecific antibody therapy.
Blood
; 143(16): 1565-1575, 2024 Apr 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-38252906
4.
Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study.
Blood
; 141(14): 1675-1684, 2023 04 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-36542826
5.
MYC overexpression in natural killer cell lymphoma: prognostic and therapeutic implications.
Haematologica
; 2024 Mar 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-38546691
6.
Benefit of axicabtagene ciloleucel versus chemoimmunotherapy in older patients and/or patients with poor ECOG performance status with relapsed or refractory large B-cell lymphoma after 2 or more lines of prior therapy.
Am J Hematol
; 99(5): 880-889, 2024 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-38504387
7.
Plain language summary of the TRANSFORM study primary analysis results: lisocabtagene maraleucel as a second treatment regimen for large B-cell lymphoma following failure of the first treatment regimen.
Future Oncol
; 2024 Mar 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-38547003
8.
Lenalidomide maintenance following high-dose therapy and autologous haematopoietic stem cell transplantation in chemo-resistant or high-risk non-Hodgkin lymphoma: A phase I/II study.
Br J Haematol
; 202(1): 116-121, 2023 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-37096954
9.
Final results of a phase II study of CHOEP plus lenalidomide as initial therapy for patients with stage II-IV peripheral T-cell lymphoma.
Br J Haematol
; 202(3): 525-529, 2023 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-37217196
10.
Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial.
Lancet
; 399(10343): 2294-2308, 2022 06 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-35717989
11.
Burkitt lymphoma in the modern era: real-world outcomes and prognostication across 30 US cancer centers.
Blood
; 137(3): 374-386, 2021 01 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-32663292
12.
Outcomes of limited stage primary bone diffuse large B-cell lymphoma in the rituximab era: a multicenter, retrospective study.
Haematologica
; 2023 Oct 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-37855051
13.
Infectious complications among CD19 CAR-T cell therapy recipients: A single-center experience.
Transpl Infect Dis
; 25 Suppl 1: e14191, 2023 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-37987114
14.
Subtype-specific and co-occurring genetic alterations in B-cell non-Hodgkin lymphoma.
Haematologica
; 107(3): 690-701, 2022 03 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33792219
15.
Phase 1 trial of carfilzomib in relapsed/refractory peripheral T-cell lymphoma.
Ann Hematol
; 101(2): 335-340, 2022 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-34668982
16.
Relapsed or Refractory Diffuse Large B-Cell Lymphoma: "Dazed and Confused".
Oncology (Williston Park)
; 36(6): 366-375, 2022 06 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-35723942
17.
Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study.
Lancet
; 396(10254): 839-852, 2020 09 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-32888407
18.
Ublituximab and umbralisib in relapsed/refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia.
Blood
; 134(21): 1811-1820, 2019 11 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-31558467
19.
Outcomes of Burkitt lymphoma with central nervous system involvement: evidence from a large multicenter cohort study.
Haematologica
; 106(7): 1932-1942, 2021 07 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33538152
20.
Romidepsin and lenalidomide-based regimens have efficacy in relapsed/refractory lymphoma: Combined analysis of two phase I studies with expansion cohorts.
Am J Hematol
; 96(10): 1211-1222, 2021 10 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34251048